Pipeline

An Innovative Pipeline

MaveriX boasts a deep pipeline of Conditionally Activated-Small Molecule Drug Conjugate (CA-SMDC) product candidates for the treatment of a broad range of solid tumors. Our differentiated technology approach has been conceived with the aim of revolutionizing targeted cancer therapy by challenging the limitations of current chemotherapy and immunotherapy.

Targeting to replace SOC chemotherapy

Program

MVX-484

Nucleoside analog

Indications

Multiple Solid Tumors

PO – daily dose schedule

Phase 1a Dose Escalation

Monotherapy FIM Q1 2025

Status:

Preclinical/ IND

Program

MVX-505

Nucleoside phosphate

Indications

Multiple Solid Tumors

IV – weekly dose schedule

Phase 1a Dose Escalation

Monotherapy FIM Q1 2025

Status:

Preclinical/ IND

Program

MVX-600 Series

Nucleotide analog

Indications

Metastatic Cancers

mCRC

Phase 1a Dose Escalation

Monotherapy

Status:

Preclinical/ IND

Targeting to replace ADC/PDC therapy

Program

MVX-700 Series

Auristatin tyramine

Indications

Metastatic Cancers

mUC

Phase 1a Dose Escalation

Monotherapy

Status:

Preclinical/ IND

Program

MVX-800 Series

Camptothecin analog

Indications

Metastatic Cancers

mBC

Phase 1a Dose Escalation

Monotherapy

Status:

Preclinical/ IND

Targeting Safer Immunotherapy

Program

MVX-200 Series

TLR7/8-Agonist

Indications

Undisclosed

Phase 1a Dose Escalation

Undisclosed

Status:

Preclinical/ IND

Program

MVX-300 Series

STING-Agonist

Indications

Undisclosed

Phase 1a Dose Escalation

Undisclosed

Status:

Preclinical/ IND